Key Takeaways
- • Qiagen appointed Jonathan Pratt as CEO effective September 1, replacing Thierry Bernard; Pratt previously led Filtration Group through a $9.25bn sale to Parker Hannifin, bringing M&A execution experience to the molecular diagnostics company.
- • The company is actively pursuing a strategic review that could result in a private equity acquisition, with a data room now open for prospective buyer due diligence.
- • EQT and KKR are among private equity firms assessing potential bids, with some buyers also exploring partnerships with strategic industry players; discussions remain ongoing with no guarantee of an offer.
- • Qiagen's market capitalization stands at approximately $8.8bn at current trading levels ($42.57 per share, down 3.4%), though some prospective bidders had previously considered offers at $50 per share or higher.
- • A successful takeover would rank among Europe's larger healthcare transactions in 2026 and potentially resolve years of ownership speculation for the molecular testing technology provider.
Summary
Qiagen has installed Jonathan Pratt as chief executive officer, effective September 1, 2026, signaling the company's commitment to navigating an active strategic review process that could culminate in a private equity acquisition. Pratt's appointment directly addresses investor and stakeholder expectations around deal execution capability. His most recent role leading Filtration Group, where he stewarded the industrial technology company through its $9.25bn cash sale to Parker Hannifin, positions him as an executive with contemporary, large-scale M&A experience. He succeeds Thierry Bernard in the role.
The timing of the CEO transition coincides with a material escalation in Qiagen's sales process. The company has now established a data room, providing prospective acquirers structured access to operational and financial information as part of formal due diligence. This represents a clear progression beyond preliminary exploration into an active transaction framework. According to Bloomberg's reporting, EQT and KKR are among the private equity firms actively evaluating potential bids. Additionally, some prospective buyers are exploring potential partnership structures with strategic industry participants alongside standalone acquisition scenarios.
Market reaction has been mixed. Qiagen shares traded 3.4% lower at $42.57 on the trading day following the announcement, placing the company's market capitalization at approximately $8.8bn. This valuation contrasts with earlier indications that some potential bidders had contemplated offers in the $50-per-share range, suggesting current market pricing may reflect deal execution uncertainty or the broader valuation environment for European healthcare assets.
The company specializes in molecular testing technologies and diagnostic services to pharmaceutical companies, research organizations, and clinical laboratories—a sector increasingly attractive to large-cap PE firms. While discussions remain active, the parties have made clear that no buyer has submitted a binding offer, and there remains no certainty that the strategic review will conclude with a transaction. Should a deal materialize, however, it would represent one of Europe's most significant healthcare acquisitions in 2026 and mark a definitive resolution to longstanding questions regarding Qiagen's long-term ownership structure.
The timing of the CEO transition coincides with a material escalation in Qiagen's sales process. The company has now established a data room, providing prospective acquirers structured access to operational and financial information as part of formal due diligence. This represents a clear progression beyond preliminary exploration into an active transaction framework. According to Bloomberg's reporting, EQT and KKR are among the private equity firms actively evaluating potential bids. Additionally, some prospective buyers are exploring potential partnership structures with strategic industry participants alongside standalone acquisition scenarios.
Market reaction has been mixed. Qiagen shares traded 3.4% lower at $42.57 on the trading day following the announcement, placing the company's market capitalization at approximately $8.8bn. This valuation contrasts with earlier indications that some potential bidders had contemplated offers in the $50-per-share range, suggesting current market pricing may reflect deal execution uncertainty or the broader valuation environment for European healthcare assets.
The company specializes in molecular testing technologies and diagnostic services to pharmaceutical companies, research organizations, and clinical laboratories—a sector increasingly attractive to large-cap PE firms. While discussions remain active, the parties have made clear that no buyer has submitted a binding offer, and there remains no certainty that the strategic review will conclude with a transaction. Should a deal materialize, however, it would represent one of Europe's most significant healthcare acquisitions in 2026 and mark a definitive resolution to longstanding questions regarding Qiagen's long-term ownership structure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.